Table 1.
Cost (investment, fixed cost and variable cost (in US$)) and summary of all types of salt (industrial salt, coarse and fine single-fortified salt, and coarse and fine double-fortified salt) produced (tons) from 2013–2018.
Fig 1.
Forecasts of the break-even years of the salt enterprise.
Results are shown from using a simple linear model to project forward the total project costs and revenues (in US$). (a) Forecast of break-even year using total cost and total revenue data calculated for 2013–2018 given in Table 2. (b) Forecast of break-even year using total cost and total revenue data calculated for 2016–2018 given in Table 2. The red dotted line indicates the break-even point for each scenario.
Table 2.
Year wise details of total cost, total revenue and net cash flow attained by the Haiti salt enterprise between 2013 to 2018.
The total costs shown are calculated using the cost data for the production of all three types of salt, while total revenue is calculated using the revenue data from the sale of all three types of salt for each year.
Fig 2.
Revenue and production cost for industrial, single-fortified and double-fortified salt.
Both revenue and production cost (in US$) for each salt are shown per ton.
Table 3.
Marginal cost of manufacturing DEC-medicated salt.
This was evaluated by analysis of the difference in the variable costs of producing the single-fortified (which included only potassium iodate) versus the double-fortified (both potassium iodate and DEC included) salt types, given that the investment and fixed costs going into manufacturing all salt types were shared equally between each type.
Table 4.
Details of production of double-fortified (DEC-medicated) salt (tons), its potential demand/year, and coverage in Léogâne Arrondissement.
Fig 3.
Timelines to reach the WHO recommended 1% mf threshold for MDA implanted at 65% and 80% coverage and DEC-medicated salt at 65%, 80%, and actual population coverages.
The median model predicted trajectory is shown for each intervention strategy. The black dotted horizontal line indicates the WHO recommended 1% mf prevalence threshold. The blue, red, sky blue, purple and green dotted vertical lines indicate the time points to reach 1% mf threshold using either MDA at 65% and 80% coverages or DEC Salt at 65%, 80%, and actual coverage, respectively.
Table 5.
Forecast of the population of Léogâne, annual cost of supplying double- fortified (DEC-medicated) salt per person per year, and total costs of treatment with DEC-medicated salt and MDA respectively for the years 2013–2027.
The population growth rate for Haiti estimated in year 2015 (1.28%) was used in making the population size estimations shown in the Table, whereas a simple linear model based on the cost and revenue data connected with DEC-medicated salt production and sale (both fine- and coarse salt types) for the years 2013–2018 (Fig 2) was used to forecast the annual cost of salt-based DEC treatments per person and for the total population between 2019–2027.
Table 6.
Comparison of total costs and CE ratios of population treatment using MDA versus supply of DEC-medicated salt for different drug coverages and DEC salt costs.